SEC Tracker
Get the app

biote BTMD

biote reports third quarter 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Revenue of $43.3 million
  2. Net income of $0.6 million
  3. Adjusted EBITDA of $5.1 million
  4. Revenue declined 9.6% from prior year

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when biote files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. Assembly Biosciences ASMB public float $98M, Jun 30, 2025
  2. Milestone Pharmaceuticals MIST public float $99M, Jun 30, 2025
  3. DiaMedica Therapeutics DMAC public float $96M, Jun 30, 2025
  4. Carisma Therapeutics CARM
  5. Larimar Therapeutics LRMR public float $95M, Jun 30, 2025